ReviewFrontiers in surgery2026
Pathophysiological mechanisms and clinical management of type 2 diabetes mellitus complicated with anal fistula.
Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The comorbidity of type 2 diabetes mellitus (T2DM) and anal fistula is a prevalent global clinical challenge. Anal fistula is the second most common anorectal disease, with an incidence 1.81-2.01 times higher in diabetic patients than in the general population. Diabetic patients face elevated risks of postoperative infection, delayed healing, and recurrence, closely linked to poor preoperative glycemic control. Current strategies are mostly extrapolated from general population guidelines, failing to address the unique metabolic, immune, and microcirculatory abnormalities in this group, leading to suboptimal outcomes. Methods: This narrative review followed PRISMA 2020 guidelines. We systematically searched PubMed, Embase, Cochrane Library, and CNKI for literature (2018-June 2024) on T2DM complicated with cryptoglandular anal fistula, including clinical studies, high-quality animal experiments, and systematic reviews. Exclusion criteria: type 1/gestational diabetes, Crohn's-related fistulas, case reports ( Results: ① Sphincter-preserving surgeries (LIFT, VAAFT, TROPIS, EAF) reduce incontinence risk; TROPIS achieved 87.6% long-term healing in diabetics, while EAF is well-established for complex fistulas. ② Regenerative therapies (CGF, MSCs) promote healing; autologous MSC-based therapies yielded 68.4%-84.6% healing for complex fistulas, with superior safety/operability vs. allogeneic products. ③ Preoperative HbA1c < 7.0% reduced infection to 8.2%, with perioperative glucose targets of 140-180 mg/dL optimal; once-weekly insulin icodec improved compliance. Conclusions: Individualized multidisciplinary strategies tailored to fistula complexity and glycemic status are essential. Future large-scale RCTs in diabetic patients are needed to validate novel biomaterials and anti-inflammatory agents to optimize outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.